CA2984618C - Histone deacetylase inhibitors and compositions and methods of use thereof - Google Patents
Histone deacetylase inhibitors and compositions and methods of use thereof Download PDFInfo
- Publication number
- CA2984618C CA2984618C CA2984618A CA2984618A CA2984618C CA 2984618 C CA2984618 C CA 2984618C CA 2984618 A CA2984618 A CA 2984618A CA 2984618 A CA2984618 A CA 2984618A CA 2984618 C CA2984618 C CA 2984618C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- mixture
- azabicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158363P | 2015-05-07 | 2015-05-07 | |
| US62/158,363 | 2015-05-07 | ||
| PCT/US2016/031335 WO2016179554A1 (en) | 2015-05-07 | 2016-05-06 | Histone deacetylase inhibitors and compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2984618A1 CA2984618A1 (en) | 2016-11-10 |
| CA2984618C true CA2984618C (en) | 2024-01-09 |
Family
ID=57218014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2984618A Active CA2984618C (en) | 2015-05-07 | 2016-05-06 | Histone deacetylase inhibitors and compositions and methods of use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10053434B2 (enExample) |
| EP (1) | EP3291810B1 (enExample) |
| JP (1) | JP6805172B2 (enExample) |
| KR (1) | KR20180002729A (enExample) |
| CN (1) | CN107735088B (enExample) |
| AU (1) | AU2016258188B2 (enExample) |
| CA (1) | CA2984618C (enExample) |
| EA (1) | EA036965B1 (enExample) |
| IL (1) | IL255448B2 (enExample) |
| MX (1) | MX378983B (enExample) |
| WO (1) | WO2016179554A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016179554A1 (en) * | 2015-05-07 | 2016-11-10 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| EP3291809B1 (en) | 2015-05-07 | 2021-08-25 | CHDI Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| EP3487843A1 (en) * | 2016-07-22 | 2019-05-29 | Syngenta Participations AG | Microbiocidal oxadiazole derivatives |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| CN109627207A (zh) * | 2018-12-17 | 2019-04-16 | 天津药明康德新药开发有限公司 | 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法 |
| WO2021021979A2 (en) | 2019-07-30 | 2021-02-04 | Eikonizo Therapapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| US20240327361A1 (en) * | 2021-02-15 | 2024-10-03 | The Research Foundation For The State University Of New York | Radiolabeled compositions and methods of use thereof |
| EP4504190A4 (en) | 2022-04-08 | 2026-03-25 | Eikonizo Therapeutics Inc | OXADIAZOLE HDAC6 INHIBITORS AND THEIR USES |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005313108B2 (en) | 2004-12-10 | 2011-05-26 | Msd Italia S.R.L. | Heterocycle derivatives as histone deacetylase (HDAC) inhibitors |
| KR101781663B1 (ko) | 2010-01-13 | 2017-09-25 | 템페로 파마슈티칼즈, 인크. | 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법 |
| WO2013006408A1 (en) * | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| CN103764635B (zh) * | 2011-07-08 | 2016-01-20 | 诺华股份有限公司 | 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途 |
| WO2013009830A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| BR112014004741B1 (pt) * | 2011-08-30 | 2021-10-13 | Chdi Foundation, Inc | Entidade química, seu uso e composição farmacêutica compreendendo a mesma |
| WO2013066835A2 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066833A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| EP2785713B1 (en) | 2011-11-28 | 2016-09-07 | Novartis AG | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| US9822058B2 (en) * | 2012-04-05 | 2017-11-21 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| WO2016179554A1 (en) * | 2015-05-07 | 2016-11-10 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| EP3291809B1 (en) | 2015-05-07 | 2021-08-25 | CHDI Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| PL3328843T3 (pl) | 2015-07-27 | 2023-02-27 | Chong Kun Dang Pharmaceutical Corp. | Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca |
| RU2695227C9 (ru) | 2015-07-27 | 2020-03-04 | Чонг Кун Данг Фармасьютикал Корп. | Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция |
| PT3331864T (pt) | 2015-08-04 | 2022-01-18 | Chong Kun Dang Pharmaceutical Corp | Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos |
-
2016
- 2016-05-06 WO PCT/US2016/031335 patent/WO2016179554A1/en not_active Ceased
- 2016-05-06 KR KR1020177034461A patent/KR20180002729A/ko not_active Withdrawn
- 2016-05-06 CA CA2984618A patent/CA2984618C/en active Active
- 2016-05-06 EA EA201792247A patent/EA036965B1/ru not_active IP Right Cessation
- 2016-05-06 MX MX2017014300A patent/MX378983B/es unknown
- 2016-05-06 AU AU2016258188A patent/AU2016258188B2/en active Active
- 2016-05-06 JP JP2017557324A patent/JP6805172B2/ja active Active
- 2016-05-06 US US15/148,907 patent/US10053434B2/en active Active
- 2016-05-06 EP EP16790203.0A patent/EP3291810B1/en active Active
- 2016-05-06 CN CN201680040061.8A patent/CN107735088B/zh active Active
-
2017
- 2017-11-06 IL IL255448A patent/IL255448B2/en unknown
-
2018
- 2018-07-26 US US16/046,254 patent/US20190202795A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3291810A4 (en) | 2018-11-07 |
| AU2016258188A1 (en) | 2017-11-23 |
| CN107735088B (zh) | 2021-11-02 |
| IL255448A0 (en) | 2017-12-31 |
| WO2016179554A1 (en) | 2016-11-10 |
| US10053434B2 (en) | 2018-08-21 |
| IL255448B2 (en) | 2023-07-01 |
| IL255448B1 (en) | 2023-03-01 |
| HK1252487A1 (en) | 2019-05-24 |
| EA201792247A1 (ru) | 2018-06-29 |
| BR112017023711A2 (pt) | 2018-07-17 |
| US20190202795A1 (en) | 2019-07-04 |
| KR20180002729A (ko) | 2018-01-08 |
| EA036965B1 (ru) | 2021-01-20 |
| AU2016258188B2 (en) | 2021-08-26 |
| EP3291810A1 (en) | 2018-03-14 |
| JP2018515489A (ja) | 2018-06-14 |
| JP6805172B2 (ja) | 2020-12-23 |
| EP3291810B1 (en) | 2022-08-10 |
| US20160326124A1 (en) | 2016-11-10 |
| CN107735088A (zh) | 2018-02-23 |
| MX2017014300A (es) | 2018-08-09 |
| CA2984618A1 (en) | 2016-11-10 |
| MX378983B (es) | 2025-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016256917B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| US10053434B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| US9783488B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| US9765054B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| US9617259B2 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| EP4072679A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| HK1252487B (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| HK1252489B (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| BR112017023711B1 (pt) | Inibidores de histona deacetilase e composições e métodos de uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210419 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250502 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250502 |